Publications by authors named "M J Postma"
Healthy working-age adults are susceptible to illness or caregiving requirements resulting from annual seasonal influenza, leading to considerable societal and economic impacts. The objective of this targeted narrative review is to understand the societal burden of influenza in terms of absenteeism and productivity loss, based on the current literature. This review includes 48 studies on the impact of influenza and influenza-like illness (ILI) and reports on the effect of influenza vaccination, age, disease severity, caring for others, comorbidities, and antiviral prophylaxis on absenteeism and productivity loss due to influenza/ILI, focusing on publications originating from Canada, Europe, and the United States.
View Article and Find Full Text PDFAim: The recent EMPA-KIDNEY trial showed evidence for preventing disease progression in adult patients with chronic kidney disease (CKD) treated with empagliflozin. It is however yet unknown if use of empagliflozin is cost effective in the Netherlands. We aimed to evaluate the cost effectiveness of empagliflozin in adult patients with CKD in the Netherlands.
View Article and Find Full Text PDFBackground: Chikungunya virus (CHIKV) outbreaks, driven by the expanding habitat of the Aedes albopictus mosquito and global climate change, pose a significant threat to public health. Our study evaluates the effectiveness of emergency vaccination using a dynamic disease transmission model for a potential large-scale outbreak in Rome, Italy.
Methods: The model incorporates a susceptible-exposed-infected-recovered (SEIR) framework for human and mosquito populations, taking into account temperature-dependent mosquito lifecycle dynamics, human-mosquito interactions, and various vaccination scenarios.
Article Synopsis
- * Between 2011 and 2020, there were 18.7 million chikungunya cases globally, resulting in 1.95 million disability-adjusted life years (DALYs), primarily affecting the Latin American and Caribbean regions.
- * The economic impact over this period was substantial, with direct costs of $2.8 billion and indirect costs reaching $47.1 billion, highlighting the need for effective resource allocation to manage this disease.